Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) currently has a daily average trading volume of 785.62K but it saw 769061 shares traded on Thursday. With a market cap of 23.97B USD, stock’s current market price of $189.66 came rising about 2.10 while comparing to the previous closing price of $185.75. In past 52 weeks, the stock remained buoying in the range of price level as high as $242.97 and as low as $117.58. In the recent trading on the day, stock has struck highest price mark of $190.09 while lowest mark touched by it was $180.78.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Taking a look at 20-day trading activity of Alnylam Pharmaceuticals Inc. (ALNY) gives us an average price of $195.20, while its current price level is -21.94% below from 52-week high level whereas it is 61.30% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $213.89 while that of 200 days or SMA-200 reads an average of $197.87. A closer look into the stock’s movement over the week reveals that its volatility is standing at 3.52% during that period while stretching the period over a month that increases to 3.80%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 39.42 which implies that the stock is in neutral territory.
Alnylam Pharmaceuticals Inc. (ALNY)’s stock is currently under the radar of 25 analysts who are in consensus at a 12-month price target range of between $136.00 and $415.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $136.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $415.00. Average price target assigned by them is $247.92 which highlights an upside potential of 23.5% for the stock over that period. And to attain the median price target of $250.00 assigned by those analysts, stock has to add about 24.14% of value to its current levels.
Data by FactSet Research shows that 25 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 1 are advising it as an Overweight. 16 analysts suggested the investors to Buy the stock while 8 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Overweight for the stock and that issued by Wall Street to investors is Moderate Buy.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Canaccord Genuity which initiated the stock as “Buy” in its note to investors issued on January 18, 2023, recommending a price target of $310 for it. Cantor Fitzgerald also issued its recommendations for the stock as it initiated the price target for the stock is $175.
Over the week, ALNY’s stock price is moving 2.00% up while it is -15.67% when we observe its performance for the past one month. Year-to-date it is -20.19% down and over the past year, the stock is showing an upside performance of 24.03%.
The latest quarterly earnings report issued by the company was for quarter ended 9/29/2022, when its quarterly earnings per share (EPS) of -$3.32 beaten by the consensus estimate of -$1.77 for the same. The company is expected to be releasing its next quarterly report in 04/27/2023, for which analysts forecasted an EPS of -$1.97 while estimate for next year EPS is -$9.46. For ALNY, analysts are forecasting an EPS-growth rate of -31.40% for current year and estimate for EPS growth in next year is 32.90%. In next quarter, company is expected to be making quarterly sales of $314.48 million as analysts are expecting the sales for current fiscal year at $1.01 billion and seeing the company making $1.48 billion in sales next year. Moreover, analysts are in estimates of $313.13 million for current-quarter revenue.
Currently, Alnylam Pharmaceuticals Inc.’s total number of outstanding shares is 123.28M with 0.52% of that held by the insiders while 97.92% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -100.80%. Stock’s beta reads 0.49. Stock has a price to sale or P/S ratio amounts to 23.10. Its return on asset (ROA) is -32.70% on average.
A filing at the U.S. Securities and Exchange Commission revealed that American Funds Growth Fund of Ame came shrinking its share ownership by 21.09% in the Alnylam Pharmaceuticals Inc. (ALNY) increasing its stake to 6.01% with control over 1.29 million shares in the company. As per SEC documents, American Funds Growth Fund of Ame shunned 7,390,927 of company’s common stock of worth $1.41 billion as per recent closing price of the stock. American Funds Growth Fund of Ame is not the only institutional holder which restructured its stake in Alnylam Pharmaceuticals Inc., as Vanguard Health Care Fund dumped 4,718,518 shares of worth $903.36 million to bring its holdings to a total of -0.32 million shares. In the most recent quarter, Vanguard Total Stock Market Index came rising its stake by 0.67% in the company and now holds 3.77 million or 3.06% of the company’s stake having worth of about 721.58 million.
Leave a Reply